Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 659 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prostate Radiation Clear all
Active, not recruiting Phase 1 Interventional

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

NCT06531499
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
AAA617, Gonadotropin-releasing hormone (GnRH) analogues, Gonadotropin-releasing hormone (GnRH) antagonists
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 4:59 PM EDT
Recruiting Phase 2 Interventional

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomography
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 4:59 PM EDT
Recruiting No phase listed Observational

Prostate Assessment with Restriction Spectrum Imaging (RSI) MRI

NCT04992728
View directory record Official record
Conditions
Prostate Cancer
Interventions
Restricted Spectrum Magnetic Resonance Imagining
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 25, 2026, 4:59 PM EDT
Completed Not applicable Interventional

Hyperthermia Plus Radiation Therapy in Treating Patients With Nonmetastatic Advanced Prostate Cancer

NCT00003045
View directory record Official record
Conditions
Prostate Cancer
Interventions
Hyperthermia, XRT
Device · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 25, 2026, 4:59 PM EDT
Recruiting Not applicable Interventional

Effectiveness of Virtual Reality (VR) in the Management of Anxiety for Patients Undergoing Radiotherapy

NCT07324577
View directory record Official record
Conditions
Radiation Therapy, Virtual Reality
Interventions
standard of care, Virtual Reality Intervention, Radiation Therapist Survey
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 4:59 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Observation of Outcomes and Side Effects of Cesium-131 in Combination With External Beam Radiation for the Treatment of Intermediate to High Risk Prostate Cancer

NCT00621413
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
IsoRay Medical, Inc.
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
9
States / cities
Phoenix, Arizona • Rancho Mirage, California • San Mateo, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 25, 2026, 4:59 PM EDT
Not listed Not applicable Interventional

Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer

NCT02334579
View directory record Official record
Conditions
Prostate Cancer, Prostatic Cancer, Prostate Neoplasms, Prostatic Neoplasms, Cancer of the Prostate
Interventions
CyberKnife Stereotactic Radiosurgery
Radiation
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

NCT00911118
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma
Interventions
Hypofractionated, image-guided, intensity-modulated external beam radiation
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
7
States / cities
Commack, New York • Harrison, New York • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 25, 2026, 4:59 PM EDT
Completed No phase listed Observational

Prostate Cancer Survey

NCT03128710
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 25, 2026, 4:59 PM EDT
Completed Not applicable Interventional

Study of Complementary Therapies in Men Receiving Radiation Therapy for Prostate Cancer: A Feasibility Trial

NCT00207259
View directory record Official record
Conditions
Prostate Cancer
Interventions
Reiki & Relaxation Response Therapy with Cognitive Restructuring
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 25, 2026, 4:59 PM EDT
Recruiting Phase 2 Interventional

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

NCT06499870
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix
Procedure · Drug · Other + 1 more
Lead sponsor
Sean Sachdev
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 4:59 PM EDT
Not listed Phase 1 Interventional

Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

NCT00969202
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Radiosurgery using the Novalis Tx
Radiation
Lead sponsor
San Diego Radiosurgery
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Escondido, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 25, 2026, 4:59 PM EDT
Completed Phase 3 Interventional

High Versus Low Dose Supplemental External Radiation With Pd-103 for Prostate Cancer

NCT00494546
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pd-103 with 20 vs 44 Gy supplemental beam XRT
Procedure
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
40 Years to 80 Years · Male only
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2007 · Synced Oct 25, 2026, 4:59 PM EDT
Recruiting Not applicable Interventional

HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer

NCT03802851
View directory record Official record
Conditions
Prostate Cancer, Lower Urinary Tract Symptoms
Interventions
Holmium Laser Enucleation of Prostate (HoLEP)
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2035
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 25, 2026, 4:59 PM EDT
Withdrawn Not applicable Interventional

Proton Therapy for High Risk Prostate Cancer

NCT01811810
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation therapy (XRT), Androgen Deprivation Therapy (ADT), Chemotherapy
Radiation · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 25, 2026, 4:59 PM EDT
Not listed Phase 3 Interventional Results available

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

NCT00567580
View directory record Official record
Conditions
Prostate Cancer
Interventions
PBRT, PLNRT, AA, LHRH agonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
444
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 25, 2026, 4:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

NCT00225420
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, leuprolide acetate, radiation therapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 25, 2026, 4:59 PM EDT
Recruiting Early Phase 1 Interventional

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

NCT03861676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal brachytherapy with PSMA PET imaging, (18F)DCFPyL
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 25, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Role of Soy Supplementation in Prostate Cancer Development

NCT00255125
View directory record Official record
Conditions
Prostate Neoplasm
Interventions
Soy Supplement, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Enzalutamide + External Beam Rt For Prostate

NCT02028988
View directory record Official record
Conditions
Intermediate Risk Prostate Cancer
Interventions
Enzalutamide, External Beam Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 25, 2026, 4:59 PM EDT
Completed No phase listed Observational

Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer

NCT00176579
View directory record Official record
Conditions
Osteoporosis, Prostate Cancer
Interventions
dual x-ray absorptiometry
Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 25, 2026, 4:59 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

NCT02572284
View directory record Official record
Conditions
Prostate Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), Prostatectomy, Quality of Life Questionnaires
Radiation · Procedure · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 25, 2026, 4:59 PM EDT
Active, not recruiting Phase 4 Interventional

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

NCT06479187
View directory record Official record
Conditions
Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
18F-rhPSMA-7.3, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 25, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

NCT02611882
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
Drug · Device
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 25, 2026, 4:59 PM EDT